Mylan, Perrigo row ahead of shareholders vote

26 August 2015
mergers-acquisitions-big

The slanging match between Netherlands-incorporated Mylan (Nasdaq: MYL) and US drugmaker Perrigo (NYSE: PRGO) has intensified ahead of the Mylan’s shareholder vote on the hostile takeover bid.

On Tuesday, Mylan reported the Irish regulators have found Perrigo making statements that could mislead shareholders and the market or may create uncertainty. Mylan said the statements violated Irish takeover rules.

Mylan executive chairman Robert Coury, said: “Perrigo continues to make misleading comments with regard to Mylan’s offer to acquire Perrigo — comments which unfortunately have been inaccurately repeated by other third parties.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical